Laekna, Inc. Advances Obesity Treatment with Promising Clinical Trial Results

The latest announcement is out from Laekna, Inc. ( (HK:2105) ).

Laekna, Inc. announced significant progress in its clinical trials for LAE102, a monoclonal antibody targeting obesity. The company completed a Phase I study in China, demonstrating promising results in muscle preservation and weight control, and has initiated a multiple ascending dose study. Additionally, Laekna has partnered with Eli Lilly to accelerate global clinical development, with a U.S. Phase I trial underway. These developments position Laekna as a key player in obesity treatment innovation, potentially impacting its market presence and offering new options for patients.

The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.46 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.

More about Laekna, Inc.

Laekna, Inc. is a biopharmaceutical company focused on the development of innovative therapies, particularly in the field of monoclonal antibodies targeting ActRII receptors. The company is engaged in clinical and pre-clinical candidate development, aiming to provide novel treatment options for conditions such as obesity.

Average Trading Volume: 4,868,500

Technical Sentiment Signal: Strong Buy

Find detailed analytics on 2105 stock on TipRanks’ Stock Analysis page.